Ocaliva obeticholic acid regulatory update

FDA’s Gastrointestinal Drugs Advisory Committee voted 17-0 that there is substantial evidence to support accelerated approval of Ocaliva obeticholic acid from Intercept to treat primary

Read the full 252 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE